Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: September Update

Performance overview

Value at beginning of month: $168,637.53

Value at end of month: $160,225.58

Month over month change: -4.99%

Total IRR: 28.90%

Related indices, monthly change

NASDAQ: -0.78%

IVV (iShares Core S&P 500): +0.54%

IBB (iShares NASDAQ Biotechnology Index): -0.18%

MXI (iShares Global Materials): +0.94%

VEGI (iShares MSCI Global Agriculture Producers): +2.21%

ICLN (iShares Clean Energy): -1.38%

Individual performances

g4165.png

The CSSBI badly underperformed all the comparable indices during September, and has almost given up the lead they had against these indices from the first part of the year. While most of the companies lost between 5% and 20% of their value, there was one positive standout in the group. Synlogic, who is developing living medicines, announced positive interim Phase I/IIa study data, which led to the company’s stock increasing 34% over the course of the month.

Changes made to index

None.

You can view the index here.

Allocation as of October 5, 2018

g4730.png

Synthetic biology investors are a mix of life sciences and traditional technology investors

Calvin Schmidt Synthetic Biology Index: August Update